Table 1.
Clinical characteristics of breast cancer patients with poor (cases) and favourable invasive disease-free survival (controls): an extreme case-control study.
| Controls | Cases | P | ||
|---|---|---|---|---|
| Number | 207 | 207 | ||
| Mean (SD) | Mean (SD) | |||
| Age, years | 47.74 (8.69) | 49.14 (10.58) | 0.140 | |
| N (%) | N (%) | |||
| Menopausal status | No | 140 (67.6) | 118 (57.0) | 0.033 |
| Yes | 67 (32.4) | 89 (43.0) | ||
| Molecular subtype | Luminal A | 12 (5.8) | 12 (5.8) | 0.999 |
| Luminal B | 119 (57.5) | 119 (57.5) | ||
| HER2 positive | 29 (14.0) | 29 (14.0) | ||
| TNBC | 32 (15.5) | 32 (15.5) | ||
| Indeterminate | 15 (7.2) | 15 (7.2) | ||
| Tumour stage | I | 58 (28.0) | 22 (10.6) | <0.001 |
| II | 118 (57.0) | 98 (47.3) | ||
| III | 31 (15.0) | 87 (42.0) | ||
| Histologic grade | I–II | 94 (45.4) | 71 (34.3) | 0.027 |
| III | 113 (54.6) | 136 (65.7) | ||
| Hormone therapy | No | 64 (30.9) | 89 (43.0) | 0.015 |
| Yes | 143 (69.1) | 118 (57.0) | ||
| Chemotherapy | No | 6 (2.9) | 11 (5.3) | 0.322 |
| Yes | 201 (97.1) | 196 (94.7) | ||
| Radiotherapy | No | 131 (63.3) | 133 (64.3) | 0.919 |
| Yes | 76 (36.7) | 74 (35.7) |
N number, SD standard deviation, HER2 human epidermal growth factor receptor 2, TNBC triple-negative breast cancer.